Is there a dose response relationship for lurbinectedin and skin reactions?

Does lurbinectedin trigger dose-related skin reactions?

Lurbinectedin causes skin reactions in some patients, but studies show no clear dose-response relationship for these effects. Clinical data from the ATLANTIS trial and other evaluations report skin reactions occurring across dose levels, but rates do not increase proportionally with higher doses.

What skin reactions do patients report?

Skin reactions include rash, pruritus, and hyperpigmentation. Hyperpigmentation appears more often in patients who received multiple cycles. Hyperpigmentation also occurs in areas exposed to pressure or friction, such as under bra straps or at site of injection.

How does lurbinectedin compare to similar drugs?

Lurbinectedin belongs to the trabectedin class of agents. Trabectedin shows dose-dependent toxicity for skin effects in some reports. Lurbinectedin replaces one carbon atom in the molecular structure of trabectedin, replacing the tetrahydroisoquinoline ring with a tetrahydrofuran ring. The modified structure may contribute to the observed flat dose-response curve for skin effects.

When does the patent expire for lurbinectedin?

The primary U.S. patent covering lurbinectedin expires in 2033. Secondary patents on formulations and methods of use extend protection into the 2035–2037 period. [1]

How do companies challenge lurbinectedin patents?

Companies challenge lurbinectedin patents through inter partes review (IPR) and other administrative proceedings. Companies file these challenges to enter biosimilar-like analogs into the market before primary patent expiry. [1]

Lurbinectedin is produced by Pharma Mar.